Logo image of HMHC

HOUGHTON MIFFLIN HARCOURT CO (HMHC) Stock Fundamental Analysis

NASDAQ:HMHC - Nasdaq - Common Stock

21.03  +0.02 (+0.1%)

After market: 21.12 +0.09 (+0.43%)

Fundamental Rating

2

Overall HMHC gets a fundamental rating of 2 out of 10. We evaluated HMHC against 73 industry peers in the Diversified Consumer Services industry. HMHC has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, HMHC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

HMHC had positive earnings in the past year.
HMHC Yearly Net Income VS EBIT VS OCF VS FCFHMHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M -200M -400M

1.2 Ratios

Industry RankSector Rank
ROA 10.82%
ROE 64.63%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HMHC Yearly ROA, ROE, ROICHMHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400 -500

1.3 Margins

Industry RankSector Rank
OM 5.41%
PM (TTM) 20.32%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HMHC Yearly Profit, Operating, Gross MarginsHMHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40

2

2. Health

2.1 Basic Checks

HMHC has more shares outstanding than it did 1 year ago.
The debt/assets ratio for HMHC has been reduced compared to a year ago.
HMHC Yearly Shares OutstandingHMHC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
HMHC Yearly Total Debt VS Total AssetsHMHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 1B 2B 3B

2.2 Solvency

HMHC has an Altman-Z score of -1.16. This is a bad value and indicates that HMHC is not financially healthy and even has some risk of bankruptcy.
HMHC has a Debt/Equity ratio of 0.96. This is a neutral value indicating HMHC is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Altman-Z -1.16
ROIC/WACCN/A
WACCN/A
HMHC Yearly LT Debt VS Equity VS FCFHMHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.39 indicates that HMHC should not have too much problems paying its short term obligations.
A Quick Ratio of 1.18 indicates that HMHC should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.18
HMHC Yearly Current Assets VS Current LiabilitesHMHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 104.02% over the past year.
Looking at the last year, HMHC shows a small growth in Revenue. The Revenue has grown by 5.80% in the last year.
Measured over the past years, HMHC shows a decrease in Revenue. The Revenue has been decreasing by -4.05% on average per year.
EPS 1Y (TTM)104.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)5.8%
Revenue growth 3Y-7.38%
Revenue growth 5Y-4.05%
Sales Q2Q%-12.18%

3.2 Future

HMHC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 67.54% yearly.
The Revenue is expected to grow by 2.84% on average over the next years.
EPS Next Y388.14%
EPS Next 2Y201.14%
EPS Next 3Y95.59%
EPS Next 5Y67.54%
Revenue Next Year3.98%
Revenue Next 2Y3.95%
Revenue Next 3Y3.37%
Revenue Next 5Y2.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HMHC Yearly Revenue VS EstimatesHMHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B
HMHC Yearly EPS VS EstimatesHMHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 300.43, which means the current valuation is very expensive for HMHC.
The average S&P500 Price/Earnings ratio is at 23.99. HMHC is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 61.55, HMHC can be considered very expensive at the moment.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.35, HMHC is valued quite expensively.
Industry RankSector Rank
PE 300.43
Fwd PE 61.55
HMHC Price Earnings VS Forward Price EarningsHMHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.11
HMHC Per share dataHMHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HMHC's earnings are expected to grow with 95.59% in the coming years.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y201.14%
EPS Next 3Y95.59%

0

5. Dividend

5.1 Amount

No dividends for HMHC!.
Industry RankSector Rank
Dividend Yield N/A

HOUGHTON MIFFLIN HARCOURT CO

NASDAQ:HMHC (4/6/2022, 8:00:02 PM)

After market: 21.12 +0.09 (+0.43%)

21.03

+0.02 (+0.1%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-24 2022-02-24/bmo
Earnings (Next)05-05 2022-05-05/bmo
Inst Owners1.13%
Inst Owner Change0%
Ins Owners0.59%
Ins Owner Change0%
Market Cap2.69B
Analysts45.71
Price Target21.42 (1.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 300.43
Fwd PE 61.55
P/S 2.56
P/FCF N/A
P/OCF N/A
P/B 8.13
P/tB N/A
EV/EBITDA 10.11
EPS(TTM)0.07
EY0.33%
EPS(NY)0.34
Fwd EY1.62%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.23
BVpS2.59
TBVpSN/A
PEG (NY)0.77
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 10.82%
ROE 64.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 5.41%
PM (TTM) 20.32%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.18
Altman-Z -1.16
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y388.14%
EPS Next 2Y201.14%
EPS Next 3Y95.59%
EPS Next 5Y67.54%
Revenue 1Y (TTM)5.8%
Revenue growth 3Y-7.38%
Revenue growth 5Y-4.05%
Sales Q2Q%-12.18%
Revenue Next Year3.98%
Revenue Next 2Y3.95%
Revenue Next 3Y3.37%
Revenue Next 5Y2.84%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A